The University of Cambridge and spinout DIOSynVax just successfully completed Phase I human trials on the world’s first fully AI-designed vaccine. The platform relies on machine learning to code a synthetic “super-antigen,” aiming to ward off entire pathogen families before they spill over to humans.
This isn’t an advancement; it is a terrifying leap int…

Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.